Osimertinib Plus Platinum–Pemetrexed Clarifies Its Advantage in EGFR-Positive Lung Cancer

Where Treatment Stands in EGFR-Positive Advanced Lung Cancer

Lung cancer remains one of the most common causes of cancer death worldwide in both men and women. Before targeted therapies emerged, patients with EGFR (epidermal growth factor receptor) mutations had options largely limited to conventional chemotherapy. Developed in 2015, osimertinibtransformed this landscape. Following FLAURA, this targeted drug became standard first-line treatment and substantially extended survival. Yet one question persisted: "Is osimertinib alone enough, or can adding chemotherapy produce even better results?"

The answer first began to take shape in 2024. On 16 February 2024, the US Food and Drug Administration (FDA), approved treatment for patients with EGFR exon 19 deletions or exon 21 L858R mutations and locally advanced or metastatic non-small cell lung cancer (NSCLC): osimertinib combined with platinum-based chemotherapy as first-line therapy. The decision was based on the FLAURA2 trial's early analysis of progression-free survival (PFS) — the combination delayed disease progression by approximately 38%.

The central remaining question concerned its effect on overall survival (OS) . The final answer was presented at the 2025 European Society for Medical Oncology Congress(ESMO 2025, LBA77) and simultaneously published in the New England Journal of Medicine. According to the final analysis, osimertinib + platinum–pemetrexed compared with osimertinib alone, increased median overall survival from 37.6 to 47.5 months — an extension of approximately 10 months. This is the longest median survival yet reported in EGFR-mutant advanced lung cancer.

FLAURA2 thus demonstrated how targeted therapies become more powerful when used in thoughtfully designed combinations . This is shaping future clinical practice: the choice is no longer simply chemotherapy or targeted therapy, but "the right combination at the right time".

Study Design

FLAURA2 was a large clinical study in patients with advanced EGFR-mutant lung cancer . This Phase 3 trial primarily assessed whether adding chemotherapy to the standard treatment, osimertinib, in the form of platinum + pemetrexed , extended patients' survival.

• Study Type: Phase 3, multicenter, open-label, randomized (1:1), two-arm trial.
• Treatment Arms: One group received osimertinib (80 mg/day) alone; the other received osimertinib + platinum (carboplatin AUC5 or cisplatin 75 mg/m²) + pemetrexed 500 mg/m² . After 4 chemotherapy cycles, patients switched to osimertinib + pemetrexed maintenance .
• Participants: A total of 557 patients participated. All had good performance status (ECOG 0–1); most either had no central nervous system spread or had controlled CNS disease.
• Objectives: The primary endpoint was progression-free survival (PFS) . Overall survival (OS) was a key secondary endpoint, and this article summarizes those findings.
• Data Cutoff: 12 June 2025; approximately 57% of events had occurred by then.

In brief, FLAURA2 was designed to show whether targeted therapy works better alone or with chemotherapy.

📊 Final FLAURA2 OS in Numbers

🛡️ Safety and Tolerability

Grade ≥3 adverse events: 70% (combination) vs 34% (monotherapy). Most common: myelosuppression (anemia, neutropenia, thrombocytopenia). Osimertinib Discontinuation: 12% vs 7%. ILD: ≈2% in both arms.

Side effects are more frequent during induction and decline during maintenance. Proactive supportive care is recommended (G-CSF, antiemetics, folate/B12 protocol).

Clinical Significance & Patient Selection

1. New Standard: For chemotherapy-eligible patients with 1L EGFR-mutant disease, osimertinib + platinum–pemetrexed is preferred.
2. Frailty/Comorbidity: Given the toxicity burden, monotherapy remains a reasonable alternative.
3. Biological Rationale: EGFR(+) adenocarcinomas have low thymidylate synthase → pemetrexed synergy.
4. Sequencing: Rather than monotherapy followed by chemotherapy, early combined suppression may improve OS.

Practical Treatment Tips

• Induction (4 Cycles): Carboplatin AUC5 or cisplatin 75 mg/m² + pemetrexed 500 mg/m² + osimertinib 80 mg/day
• Maintenance: Osimertinib + pemetrexed while appropriate, then osimertinib alone
• Support: Antiemetic prophylaxis, G-CSF prophylaxis when indicated, pemetrexed precautions (folic acid + B12; dexamethasone)
• CNS Monitoring: Osimertinib's CNS activity + OS benefit → monitor recurrence patterns closely with MRI

Brief FAQ

Question: Combination Treatment for Everyone?
Answer: For fit, chemotherapy-eligible patients, yes. Monotherapy may be considered in frail patients or those with comorbidities.

Question: What About Quality of Life?
Answer: PRO data support a tendency toward maintained quality of life after induction ; maintenance duration should be individualized.

Question: What Lies Ahead?
Answer: TROP2 ADCs and MET-targeted agents show promise in second-line treatment; sequencing based on resistance biology is being studied.

Quick Summary Cards

📚 Sources

1. Jänne PA, Planchard D, et al. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC. NEJM. 17 October 2025. DOI: 10.1056/NEJMoa2510308.
2. ESMO 2025 Presidential / Late-Breaking Abstracts Session, LBA77 presentation.
3. ClinicalTrials.gov: NCT04035486.

This content is intended for healthcare professionals; treatment decisions require individualized patient assessment.